{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:44:37Z","timestamp":1789919077010,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Microbial pathogenesis is a serious health concern. The threat escalates as the existing conventional antimicrobials are losing their efficacy against the evolving pathogens. Peptides hold promise to be developed into next-generation antibiotics. Antimicrobial peptides adopt amphipathic structures that could selectively bind to and disrupt the microbial membranes. Interaction of proteins with membranes is central to all living systems and we reasoned that the membrane-binding domains in microbial proteins could be developed into efficient antimicrobials. This is an interesting approach as self-like sequences could elude the microbial strategies of degrading the antimicrobial peptides, one of the mechanisms of showing resistance to antimicrobials. We selected the 9-residue-long membrane-binding region of <jats:italic>E. coli<\/jats:italic> MreB protein. The 9-residue peptide (C-terminal amide) and its N-terminal acetylated analog displayed broad-spectrum activity, killing Gram-negative bacteria, Gram-positive bacteria, and fungi. Extension with a tryptophan residue at the N-terminus drastically improved the activity of the peptides with lethal concentrations \u226410\u2009\u03bcM against all the organisms tested. The tryptophan-extended peptides caused complete killing of <jats:italic>C. albicans<\/jats:italic> as well as gentamicin and methicillin resistant <jats:italic>S. aureus<\/jats:italic> at 5\u2009\u03bcM concentration. Lipid-binding studies and electron microscopic analyses of the peptide-treated microbes suggest membrane disruption as the mechanism of killing.<\/jats:p>","DOI":"10.1038\/srep42994","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T10:18:51Z","timestamp":1487845131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Highly potent antimicrobial peptides from N-terminal membrane-binding region of E. coli MreB"],"prefix":"10.1038","volume":"7","author":[{"given":"Karabi","family":"Saikia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalavarthi Durga","family":"Sravani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibin","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"BFsrep42994_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/415389a","volume":"415","author":"M Zasloff","year":"2002","unstructured":"Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 415, 389\u2013395 (2002).","journal-title":"Nature"},{"key":"BFsrep42994_CR2","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1111\/j.1742-4658.2011.08302.x","volume":"278","author":"A Cederlund","year":"2011","unstructured":"Cederlund, A., Gudmundsson, G. H. & Agerberth, B. Antimicrobial peptides important in innate immunity. FEBS J. 278, 3942\u20133951 (2011).","journal-title":"FEBS J"},{"key":"BFsrep42994_CR3","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.1021\/ja305644e","volume":"134","author":"B Mishra","year":"2012","unstructured":"Mishra, B. & Wang, G. Ab initio design of potent anti-MRSA peptides based on database filtering technology. J. Am. Chem. Soc. 134, 12426\u201312429 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep42994_CR4","doi-asserted-by":"publisher","first-page":"24482","DOI":"10.1038\/srep24482","volume":"6","author":"L Fan","year":"2016","unstructured":"Fan, L. et al. DRAMP: a comprehensive data repository of antimicrobial peptides. Sci. Rep. 6, 24482 (2016).","journal-title":"Sci. Rep"},{"key":"BFsrep42994_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/CMR.00056-05","volume":"19","author":"H Jenssen","year":"2006","unstructured":"Jenssen, H., Hamill, P. & Hancock, R. E. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491\u2013511 (2006).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFsrep42994_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s13238-010-0004-3","volume":"1","author":"Y Huang","year":"2010","unstructured":"Huang, Y., Huang, J. & Chen, Y. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 1, 143\u2013152 (2010).","journal-title":"Protein Cell"},{"key":"BFsrep42994_CR7","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1046\/j.1432-1033.2001.02494.x","volume":"268","author":"A Giangaspero","year":"2001","unstructured":"Giangaspero, A., Sandri, L. & Tossi, A. Amphipathic alpha helical antimicrobial peptides. Eur. J. Biochem. 268, 5589\u20135600 (2001).","journal-title":"Eur. J. Biochem."},{"key":"BFsrep42994_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fmicb.2013.00412","volume":"4","author":"LS Tavares","year":"2013","unstructured":"Tavares, L. S. et al. Strategies and molecular tools to fight antimicrobial resistance: resistome, transcriptome, and antimicrobial peptides. Front. Microbiol. 4, 412 (2013).","journal-title":"Front. Microbiol"},{"key":"BFsrep42994_CR9","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","volume":"6","author":"AK Marr","year":"2006","unstructured":"Marr, A. K., Gooderham, W. J. & Hancock, R. E. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6, 468\u2013472 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFsrep42994_CR10","doi-asserted-by":"publisher","first-page":"12276","DOI":"10.3390\/molecules171012276","volume":"17","author":"MD Seo","year":"2012","unstructured":"Seo, M. D., Won, H. S., Kim, J. H., Mishig-Ochir, T. & Lee, B. J. Antimicrobial peptides for therapeutic applications: a review. Molecules 17, 12276\u201312286 (2012).","journal-title":"Molecules"},{"key":"BFsrep42994_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.molcel.2011.07.008","volume":"43","author":"J Salje","year":"2011","unstructured":"Salje, J., van den Ent, F., de Boer, P. & Lowe, J. Direct membrane binding by bacterial actin MreB. Mol. Cell 43, 478\u2013487 (2011).","journal-title":"Mol. Cell"},{"key":"BFsrep42994_CR12","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1093\/bioinformatics\/btn392","volume":"24","author":"R Gautier","year":"2008","unstructured":"Gautier, R., Douguet, D., Antonny, B. & Drin, G. HELIQUEST: a web server to screen sequences with specific alpha-helical properties. Bioinformatics 24, 2101\u20132102 (2008).","journal-title":"Bioinformatics"},{"key":"BFsrep42994_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2478\/s11658-010-0036-y","volume":"16","author":"RC Keller","year":"2011","unstructured":"Keller, R. C. The prediction of novel multiple lipid-binding regions in protein translocation motor proteins: a possible general feature. Cell Mol. Biol. Lett. 16, 40\u201354 (2011).","journal-title":"Cell Mol. Biol. Lett"},{"key":"BFsrep42994_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1128\/AAC.43.4.782","volume":"43","author":"Y Ge","year":"1999","unstructured":"Ge, Y. et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother. 43, 782\u2013788 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep42994_CR15","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1128\/AAC.49.11.4561-4566.2005","volume":"49","author":"J Varkey","year":"2005","unstructured":"Varkey, J. & Nagaraj, R. Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. Antimicrob. Agents Chemother. 49, 4561\u20134566 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep42994_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik, D. J., Fairlie, D. P., Liras, S. & Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des. 81, 136\u2013147 (2013).","journal-title":"Chem. Biol. Drug Des"},{"key":"BFsrep42994_CR17","doi-asserted-by":"publisher","first-page":"N75","DOI":"10.1097\/00003246-200104001-00004","volume":"29","author":"GW Waterer","year":"2001","unstructured":"Waterer, G. W. & Wunderink, R. G. Increasing threat of Gram-negative bacteria. Crit. Care Med. 29, N75\u201381 (2001).","journal-title":"Crit. Care Med."},{"key":"BFsrep42994_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jhin.2005.07.009","volume":"62","author":"F Daxboeck","year":"2006","unstructured":"Daxboeck, F., Budic, T., Assadian, O., Reich, M. & Koller, W. Economic burden associated with multi-resistant Gram-negative organisms compared with that for methicillin-resistant Staphylococcus aureus in a university teaching hospital. J. Hosp. Infect. 62, 214\u2013218 (2006).","journal-title":"J. Hosp. Infect."},{"key":"BFsrep42994_CR19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","volume":"22","author":"PD Lister","year":"2009","unstructured":"Lister, P. D., Wolter, D. J. & Hanson, N. D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22, 582\u2013610 (2009).","journal-title":"Clin. Microbiol. Rev."},{"key":"BFsrep42994_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1021\/bm900896h","volume":"11","author":"C Zhou","year":"2010","unstructured":"Zhou, C. et al. High potency and broad-spectrum antimicrobial peptides synthesized via ring-opening polymerization of alpha-aminoacid-N-carboxyanhydrides. Biomacromolecules 11, 60\u201367 (2010).","journal-title":"Biomacromolecules"},{"key":"BFsrep42994_CR21","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1073\/pnas.80.21.6475","volume":"80","author":"D Andreu","year":"1983","unstructured":"Andreu, D., Merrifield, R. B., Steiner, H. & Boman, H. G. Solid-phase synthesis of cecropin A and related peptides. Proc. Natl. Acad. Sci. USA 80, 6475\u20136479 (1983).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep42994_CR22","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1432-1033.1991.tb16442.x","volume":"202","author":"B Agerberth","year":"1991","unstructured":"Agerberth, B. et al. Amino acid sequence of PR-39. Eur. J. Biochem. 202, 849\u2013854 (1991).","journal-title":"Eur. J. Biochem."},{"key":"BFsrep42994_CR23","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.bbamem.2012.12.002","volume":"1828","author":"IM Torcato","year":"2013","unstructured":"Torcato, I. M. et al. Design and characterization of novel antimicrobial peptides, R-BP100 and RW-BP100, with activity against Gram-negative and Gram-positive bacteria. Biochim. Biophys. Acta 1828, 944\u2013955 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFsrep42994_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nrmicro2200","volume":"7","author":"HF Chambers","year":"2009","unstructured":"Chambers, H. F. & Deleo, F. R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7, 629\u2013641 (2009).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFsrep42994_CR25","doi-asserted-by":"publisher","first-page":"7687","DOI":"10.1073\/pnas.122108599","volume":"99","author":"MC Enright","year":"2002","unstructured":"Enright, M. C. et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc. Natl. Acad. Sci. USA 99, 7687\u20137692 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep42994_CR26","doi-asserted-by":"publisher","first-page":"9657","DOI":"10.1038\/srep09657","volume":"5","author":"KY Lum","year":"2015","unstructured":"Lum, K. Y. et al. Activity of Novel Synthetic Peptides against Candida albicans. Sci. Rep. 5, 9657 (2015).","journal-title":"Sci. Rep"},{"key":"BFsrep42994_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbrc.2007.08.162","volume":"363","author":"SR Dennison","year":"2007","unstructured":"Dennison, S. R., Baker, R. D., Nicholl, I. D. & Phoenix, D. A. Interactions of cell penetrating peptide Tat with model membranes: a biophysical study. Biochem. Biophys. Res. Commun. 363, 178\u2013182 (2007).","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42994","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42994.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:35:07Z","timestamp":1671845707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,24]]}},"alternative-id":["BFsrep42994"],"URL":"https:\/\/doi.org\/10.1038\/srep42994","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]},"assertion":[{"value":"31 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42994"}}